AMAG Pharmaceuticals Submits a New Drug Application to the U.S. Food and Drug Administration for Bremelanotide for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women
26 mars 2018 08h00 HE
|
AMAG Pharmaceuticals, Inc.
WALTHAM, Mass., March 26, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug...
AMAG Pharmaceuticals to Present at Upcoming Investor Conferences
05 mars 2018 08h00 HE
|
AMAG Pharmaceuticals, Inc.
WALTHAM, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences: Cowen and...
AMAG Reports 2017 Financial Results and Company Update
27 févr. 2018 07h00 HE
|
AMAG Pharmaceuticals, Inc.
2017 GAAP Revenue Increased 15% Year-over-Year February 2018: Company Secures Two U.S. Food and Drug Administration (FDA) Approvals Conference Call Scheduled for 8:00 a.m. ET Today WALTHAM, Mass.,...
AMAG Pharmaceuticals to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call and Webcast on Tuesday, February 27, 2018 at 8:00 a.m. ET
20 févr. 2018 08h00 HE
|
AMAG Pharmaceuticals, Inc.
WALTHAM, Mass., Feb. 20, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that its fourth quarter and full year 2017 financial results will be released on Tuesday,...
AMAG Pharmaceuticals Announces FDA Approval of Makena® (hydroxyprogesterone caproate injection) Subcutaneous Auto-Injector to Reduce the Risk of Preterm Birth in Certain At-Risk Women
14 févr. 2018 18h03 HE
|
AMAG Pharmaceuticals, Inc.
WALTHAM, Mass., Feb. 14, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the U.S. Food and Drug Administration (FDA) approved the Makena® subcutaneous...
AMAG Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application (sNDA) for Feraheme® (ferumoxytol injection)
05 févr. 2018 08h00 HE
|
AMAG Pharmaceuticals, Inc.
WALTHAM, Mass., Feb. 05, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the U.S. Food and Drug Administration (FDA) has approved its application to broaden...
AMAG Pharmaceuticals Announces Preliminary 2017 Financial Results and Provides 2018 Guidance
08 janv. 2018 08h00 HE
|
AMAG Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 08, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today provided a business update, including preliminary unaudited fourth quarter and full year 2017...
AMAG Pharmaceuticals Awards $300,000 in Grants to Further Research in Preterm Birth and Neonatal Health
21 déc. 2017 08h00 HE
|
AMAG Pharmaceuticals, Inc.
WALTHAM, Mass., Dec. 21, 2017 (GLOBE NEWSWIRE) -- As part of the company’s ongoing support of maternal and neonatal health, AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced it has awarded...
AMAG Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference
20 déc. 2017 16h01 HE
|
AMAG Pharmaceuticals, Inc.
WALTHAM, Mass., Dec. 20, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that William Heiden, president and chief executive officer, will present at the 36th Annual...
New Patent Issued to AMAG Pharmaceuticals Entitled "Methods of Reducing Risk of Preterm Birth"
20 déc. 2017 08h00 HE
|
AMAG Pharmaceuticals, Inc.
WALTHAM, Mass., Dec. 20, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the issuance of U.S. Patent Number 9,844,558 entitled “Methods of Reducing Risk of Preterm...